{"url_path":"/sec/mgrx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1938046/0001493152-26-024426-index.html","accession_number":"0001493152-26-024426","cik":"0001938046","ticker":"MGRX","issuer_name":"MANGOCEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1938046/0001493152-26-024426-index.html","primary_entity_key":"0001938046","primary_entity_name":"MANGOCEUTICALS, INC."},"word_count":3605,"has_tables":true,"body_markdown":"false\nQ1\n--12-31\n0001938046\n\n0001938046\n\n2026-01-01\n2026-03-31\n\n0001938046\n\n2026-05-15\n\n0001938046\n\n2026-03-31\n\n0001938046\n\n2025-12-31\n\n0001938046\n\nus-gaap:NonrelatedPartyMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:NonrelatedPartyMember\n\n2025-12-31\n\n0001938046\n\nus-gaap:RelatedPartyMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:RelatedPartyMember\n\n2025-12-31\n\n0001938046\n\nMGRX:PatentPurchasePayableMember\n\n2026-03-31\n\n0001938046\n\nMGRX:PatentPurchasePayableMember\n\n2025-12-31\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2026-03-31\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-12-31\n\n0001938046\n\nMGRX:SeriesCConvertiblePreferredStockMember\n\n2026-03-31\n\n0001938046\n\nMGRX:SeriesCConvertiblePreferredStockMember\n\n2025-12-31\n\n0001938046\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nus-gaap:PreferredStockMember\nus-gaap:PreferredClassBMember\n\n2024-12-31\n\n0001938046\n\nMGRX:PreferredClassCMember\nus-gaap:PreferredStockMember\n\n2024-12-31\n\n0001938046\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001938046\n\nus-gaap:WarrantMember\n\n2024-12-31\n\n0001938046\n\nMGRX:SubscriptionReceivableMember\n\n2024-12-31\n\n0001938046\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001938046\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001938046\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2024-12-31\n\n0001938046\n\nus-gaap:NoncontrollingInterestMember\n\n2024-12-31\n\n0001938046\n\n2024-12-31\n\n0001938046\n\nus-gaap:PreferredStockMember\nus-gaap:PreferredClassBMember\n\n2025-12-31\n\n0001938046\n\nMGRX:PreferredClassCMember\nus-gaap:PreferredStockMember\n\n2025-12-31\n\n0001938046\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001938046\n\nus-gaap:WarrantMember\n\n2025-12-31\n\n0001938046\n\nMGRX:SubscriptionReceivableMember\n\n2025-12-31\n\n0001938046\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001938046\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001938046\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-12-31\n\n0001938046\n\nus-gaap:NoncontrollingInterestMember\n\n2025-12-31\n\n0001938046\n\nus-gaap:PreferredStockMember\nus-gaap:PreferredClassBMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nMGRX:PreferredClassCMember\nus-gaap:PreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nus-gaap:WarrantMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nMGRX:SubscriptionReceivableMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nus-gaap:NoncontrollingInterestMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nus-gaap:PreferredStockMember\nus-gaap:PreferredClassBMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nMGRX:PreferredClassCMember\nus-gaap:PreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nMGRX:SubscriptionReceivableMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:NoncontrollingInterestMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:PreferredStockMember\nus-gaap:PreferredClassBMember\n\n2025-03-31\n\n0001938046\n\nMGRX:PreferredClassCMember\nus-gaap:PreferredStockMember\n\n2025-03-31\n\n0001938046\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001938046\n\nus-gaap:WarrantMember\n\n2025-03-31\n\n0001938046\n\nMGRX:SubscriptionReceivableMember\n\n2025-03-31\n\n0001938046\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001938046\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001938046\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-03-31\n\n0001938046\n\nus-gaap:NoncontrollingInterestMember\n\n2025-03-31\n\n0001938046\n\n2025-03-31\n\n0001938046\n\nus-gaap:PreferredStockMember\nus-gaap:PreferredClassBMember\n\n2026-03-31\n\n0001938046\n\nMGRX:PreferredClassCMember\nus-gaap:PreferredStockMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:WarrantMember\n\n2026-03-31\n\n0001938046\n\nMGRX:SubscriptionReceivableMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:NoncontrollingInterestMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:RelatedPartyMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:RelatedPartyMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nus-gaap:NonrelatedPartyMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:NonrelatedPartyMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nus-gaap:IPOMember\n\n2023-03-01\n2023-03-31\n\n0001938046\n\nus-gaap:IPOMember\n\n2023-03-31\n\n0001938046\n\nMGRX:ResaleProspectusMember\n\n2023-03-01\n2023-03-31\n\n0001938046\n\nMGRX:ResaleProspectusMember\n\n2023-03-31\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:SeriesBPreferredStockMember\n\n2025-01-03\n2025-01-03\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:WarrantMember\n\n2025-01-03\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:SeriesBPreferredStockMember\n\n2025-01-06\n2025-01-06\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:WarrantMember\n\n2025-01-06\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:SeriesBPreferredStockMember\n\n2025-09-30\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:SeriesBPreferredStockMember\n\n2025-01-01\n2025-12-31\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:WarrantMember\n\n2025-12-31\n\n0001938046\n\nus-gaap:SeriesAPreferredStockMember\n\n2025-01-09\n\n0001938046\n\nus-gaap:SeriesAPreferredStockMember\n\n2025-01-09\n2025-01-09\n\n0001938046\n\nMGRX:JacobCohenMember\n\n2025-01-30\n2025-01-30\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-01-15\n2025-01-15\n\n0001938046\n\nMGRX:AmendmentLetterMember\n\n2026-03-31\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-02-12\n2025-02-12\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-02-12\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockDesignationMember\nMGRX:SeriesBDesignationMember\n\n2025-03-17\n2025-03-17\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-04-03\n2025-04-03\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-04-03\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\nMGRX:SecuritiesPurchaseAgreementMember\n\n2025-04-11\n2025-04-11\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-04-28\n2025-04-28\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-04-28\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-05-01\n2025-05-01\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-05-01\n\n0001938046\n\nMGRX:JacobCohenMember\nus-gaap:CommonStockMember\n\n2025-05-13\n2025-05-13\n\n0001938046\n\nus-gaap:PreferredStockMember\nMGRX:JacobCohenMember\n\n2025-05-13\n2025-05-13\n\n0001938046\n\nus-gaap:CommonStockMember\nMGRX:JacobCohenMember\n\n2025-05-13\n\n0001938046\n\nMGRX:JacobCohenMember\n\n2025-05-13\n2025-05-13\n\n0001938046\n\nMGRX:ClarificationAgreementMember\n\n2026-05-18\n2026-05-18\n\n0001938046\n\nMGRX:ClarificationAgreementMember\n\n2026-05-18\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-06-05\n2025-06-05\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-06-05\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-09-16\n2025-09-16\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-09-16\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-10-16\n2025-10-16\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-10-16\n\n0001938046\n\n2025-12-18\n2025-12-18\n\n0001938046\n\n2025-12-18\n\n0001938046\n\n2025-12-24\n\n0001938046\n\nus-gaap:PrivatePlacementMember\n\n2025-12-24\n2025-12-24\n\n0001938046\n\nus-gaap:IPOMember\nus-gaap:WarrantMember\n\n2025-12-24\n2025-12-24\n\n0001938046\n\nMGRX:MangoRxMexicoMember\n\n2025-12-31\n\n0001938046\n\nMGRX:MangoRxUKLimitedMember\n\n2025-12-31\n\n0001938046\n\nMGRX:MangoAndPeachesMember\n\n2025-12-31\n\n0001938046\n\nMGRX:MangoRxIPHoldingsLLCMember\n\n2025-12-31\n\n0001938046\n\nMGRX:MangoRxMexicoMember\n\n2024-12-13\n\n0001938046\n\nMGRX:MangoRxUKLimitedMember\n\n2024-12-13\n\n0001938046\n\nMGRX:MangoRxMexicoMember\n\n2026-03-31\n\n0001938046\n\nMGRX:ThirdPartiesMember\n\n2026-03-31\n\n0001938046\n\nMGRX:MangoAndPeachesCorpMember\n\n2026-03-31\n\n0001938046\n\nMGRX:MangoAndPeachesCorpMember\n\n2026-03-31\n\n0001938046\n\nMGRX:MAndPandMrCohenMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:PatentsMember\nsrt:MinimumMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:PatentsMember\nsrt:MaximumMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:PatentsMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nMGRX:MasterDistributionAgreementMember\nMGRX:PropreEnergieIncMember\n\n2025-01-30\n2025-01-30\n\n0001938046\n\nMGRX:MasterDistributionAgreementMember\nMGRX:PropreEnergieIncMember\n\n2025-01-30\n\n0001938046\n\nMGRX:MasterDistributionAgreementMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nMGRX:MasterDistributionAgreementMember\n\n2025-01-01\n2025-12-31\n\n0001938046\n\nMGRX:OptionsMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:DerivativeMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nMGRX:OptionsMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nus-gaap:WarrantMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nus-gaap:DerivativeMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nsrt:MinimumMember\n\n2026-03-31\n\n0001938046\n\nsrt:MaximumMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:PatentsMember\n\n2026-03-31\n\n0001938046\n\nMGRX:MasterDistributionAgreementMember\n\n2026-03-31\n\n0001938046\n\nMGRX:PeriodEndSpotRateMember\n\n2026-03-31\n\n0001938046\n\nMGRX:PeriodEndSpotRateMember\ncountry:MX\n\n2026-03-31\n\n0001938046\n\nMGRX:PeriodEndSpotRateMember\n\n2025-12-31\n\n0001938046\n\nMGRX:PeriodEndSpotRateMember\ncountry:MX\n\n2025-12-31\n\n0001938046\n\nMGRX:AverageRateMember\n\n2026-03-31\n\n0001938046\n\nMGRX:AverageRateMember\ncountry:MX\n\n2026-03-31\n\n0001938046\n\nMGRX:AverageRateMember\n\n2025-12-31\n\n0001938046\n\nMGRX:AverageRateMember\ncountry:MX\n\n2025-12-31\n\n0001938046\n\nus-gaap:FairValueInputsLevel1Member\n\n2026-03-31\n\n0001938046\n\nus-gaap:FairValueInputsLevel2Member\n\n2026-03-31\n\n0001938046\n\nus-gaap:FairValueInputsLevel3Member\n\n2026-03-31\n\n0001938046\n\nus-gaap:FairValueInputsLevel1Member\n\n2025-12-31\n\n0001938046\n\nus-gaap:FairValueInputsLevel2Member\n\n2025-12-31\n\n0001938046\n\nus-gaap:FairValueInputsLevel3Member\n\n2025-12-31\n\n0001938046\n\nMGRX:ComputersMember\n\n2026-03-31\n\n0001938046\n\nMGRX:ComputersMember\n\n2025-12-31\n\n0001938046\n\nus-gaap:EquipmentMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:EquipmentMember\n\n2025-12-31\n\n0001938046\n\n2022-10-01\n\n0001938046\n\n2025-11-01\n\n0001938046\n\nMGRX:LeaseTwoMember\n\n2026-03-31\n\n0001938046\n\nMGRX:LeaseTwoMember\n\n2025-12-31\n\n0001938046\n\n2025-09-01\n\n0001938046\n\nMGRX:LeaseThreeMember\n\n2026-03-31\n\n0001938046\n\nMGRX:LeaseThreeMember\n\n2025-12-31\n\n0001938046\n\nMGRX:CohenEnterprisesIncMember\n\n2024-10-18\n\n0001938046\n\nMGRX:CohenEnterprisesIncMember\n\n2024-03-18\n\n0001938046\n\nMGRX:CohenEnterprisesIncMember\n\n2024-04-01\n\n0001938046\n\nMGRX:CohenEnterprisesIncMember\n\n2024-12-13\n2024-12-13\n\n0001938046\n\nMGRX:TheTigerCubTrustMember\n\n2025-05-02\n\n0001938046\n\nMGRX:TheTigerCubTrustMember\n\n2025-05-02\n2025-05-02\n\n0001938046\n\nMGRX:TheTigerCubTrustMember\n\n2025-12-19\n2025-12-19\n\n0001938046\n\nMGRX:TheTigerCubTrustMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nMGRX:TheTigerCubTrustMember\n\n2025-07-31\n\n0001938046\n\nMGRX:TheTigerCubTrustMember\n\n2025-07-21\n2025-07-21\n\n0001938046\n\nMGRX:TheTigerCubTrustMember\n\n2026-03-31\n\n0001938046\n\nMGRX:TheTigerCubTrustMember\n\n2025-07-21\n\n0001938046\n\nMGRX:TheTigerCubTrustMember\n\n2025-12-04\n\n0001938046\n\nMGRX:TheTigerCubTrustMember\n\n2025-12-19\n\n0001938046\n\nMGRX:CohenEnterprisesIncMember\nMGRX:MillEndCapitalLtdMember\n\n2024-12-13\n\n0001938046\n\nMGRX:DebtConversionAgreementMember\nMGRX:MillEndCapitalLtdMember\n\n2024-12-13\n\n0001938046\n\nMGRX:DebtConversionAgreementMember\nMGRX:MillEndCapitalLtdMember\n\n2025-01-15\n\n0001938046\n\nMGRX:DebtConversionAgreementMember\nMGRX:MillEndCapitalLtdMember\n\n2025-01-15\n2025-01-15\n\n0001938046\n\nMGRX:IndigoCapitalLPMember\n\n2025-04-15\n\n0001938046\n\nMGRX:IndigoCapitalLPMember\n\n2025-04-15\n2025-04-15\n\n0001938046\n\nMGRX:AgreementToAmendMember\nus-gaap:WarrantMember\n\n2025-05-27\n\n0001938046\n\nMGRX:AmendedAndRestatedPromissoryNoteMember\nus-gaap:CommonStockMember\n\n2025-05-27\n\n0001938046\n\nMGRX:AmendedAndRestatedPromissoryNoteMember\nus-gaap:CommonStockMember\n\n2025-05-27\n2025-05-27\n\n0001938046\n\nMGRX:AmendedAndRestatedPromissoryNoteMember\nus-gaap:WarrantMember\n\n2025-05-27\n\n0001938046\n\nMGRX:AmendedAndRestatedPromissoryNoteMember\nus-gaap:WarrantMember\n\n2025-05-27\n2025-05-27\n\n0001938046\n\nMGRX:IndigoCapitalLPMember\n\n2025-07-16\n\n0001938046\n\nMGRX:IndigoCapitalLPMember\n\n2025-07-16\n2025-07-16\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2024-03-28\n\n0001938046\n\n2024-03-28\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-12-31\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:WarrantMember\n\n2025-01-06\n2025-01-06\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:SeriesBPreferredStockMember\n\n2025-01-06\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-03-25\n2025-03-25\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockOneMember\n\n2025-03-25\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockOneMember\n\n2025-03-25\n2025-03-25\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockTwoMember\n\n2025-03-25\n2025-03-25\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockTwoMember\n\n2025-03-25\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-03-26\n2025-03-26\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-03-26\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-03-28\n2025-03-28\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-03-28\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockOneMember\n\n2025-03-28\n2025-03-28\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockOneMember\n\n2025-03-28\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockTwoMember\n\n2025-03-28\n2025-03-28\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockTwoMember\n\n2025-03-28\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockDesignationMember\n\n2025-03-17\n2025-03-17\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-04-03\n2025-04-03\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-04-03\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-04-28\n2025-04-28\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-04-28\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-05-01\n2025-05-01\n\n0001938046\n\nMGRX:SeriesBConvertiblePreferredStockMember\n\n2025-05-01\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-06-05\n2025-06-05\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-06-05\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-09-15\n2025-09-15\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-09-15\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-10-16\n2025-10-16\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-10-16\n\n0001938046\n\nMGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember\n\n2024-04-18\n2024-04-18\n\n0001938046\n\nMGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember\n\n2024-04-18\n\n0001938046\n\nMGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember\n\n2026-03-31\n\n0001938046\n\nMGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember\n\n2025-12-31\n\n0001938046\n\nus-gaap:SeriesCPreferredStockMember\n\n2024-04-18\n\n0001938046\n\nus-gaap:SeriesCPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:SeriesCPreferredStockMember\n\n2025-01-01\n2025-12-31\n\n0001938046\n\nMGRX:IPPurchaseAgreementMember\n\n2024-04-24\n2024-04-24\n\n0001938046\n\nMGRX:IPPurchaseAgreementMember\nus-gaap:SeriesCPreferredStockMember\n\n2024-04-24\n2024-04-24\n\n0001938046\n\nMGRX:IPPurchaseAgreementMember\nus-gaap:SeriesCPreferredStockMember\n\n2024-04-24\n\n0001938046\n\nMGRX:IPPurchaseAgreementMember\n\n2024-01-01\n2024-12-31\n\n0001938046\n\nMGRX:ConsultingAgreementMember\nMGRX:LSTMHoldingsLLCMember\n\n2026-01-01\n2026-01-01\n\n0001938046\n\nMGRX:ConsultingAgreementLSTMMember\n\n2026-01-01\n2026-12-31\n\n0001938046\n\nMGRX:ConsultingAgreementMember\nMGRX:LSTMHoldingsLLCMember\n\n2026-01-01\n\n0001938046\n\nMGRX:ConsultingAgreementLSTMMember\n\n2026-01-01\n2026-01-01\n\n0001938046\n\nMGRX:ConsultingAgreementLSTMMember\n\n2026-01-12\n2026-01-12\n\n0001938046\n\nMGRX:ConsultingAgreementLSTMMember\n\n2026-03-16\n\n0001938046\n\nMGRX:ConsultingAgreementMember\nMGRX:LSTMHoldingsLLCMember\n\n2026-01-22\n\n0001938046\n\n2026-01-22\n2026-01-22\n\n0001938046\n\nMGRX:ConsultingAgreementMuhammadAzfarMember\n\n2026-01-22\n\n0001938046\n\nMGRX:ConsultingAgreementMuhammadAzfarMember\n\n2026-01-01\n\n0001938046\n\nMGRX:ConsultingAgreementMuhammadAzfarMember\n\n2026-01-22\n2026-01-22\n\n0001938046\n\nMGRX:ConsultingAgreementMuhammadAzfarMember\n\n2026-03-13\n\n0001938046\n\nMGRX:ConsultingAgreementMuhammadAzfarMember\n\n2026-03-13\n2026-03-13\n\n0001938046\n\nMGRX:ConsultingAgreementMember\nMGRX:GatorlandHoldingsLlcMember\n\n2026-03-16\n\n0001938046\n\nMGRX:ConsultingAgreementMuhammadAzfarMember\n\n2026-03-16\n\n0001938046\n\nMGRX:ConsultingAgreementMuhammadAzfarMember\n\n2026-03-16\n2026-03-16\n\n0001938046\n\nMGRX:TwoThousandTwentyTwoEquityIncentivePlanMember\n\n2022-01-01\n2022-12-31\n\n0001938046\n\nMGRX:TwoThousandTwentyTwoEquityIncentivePlanMember\nsrt:ChiefExecutiveOfficerMember\n\n2022-01-01\n2022-12-31\n\n0001938046\n\nMGRX:TwoThousandTwentyTwoEquityIncentivePlanMember\nsrt:ChiefOperatingOfficerMember\n\n2022-01-01\n2022-12-31\n\n0001938046\n\nMGRX:TwoThousandTwentyTwoEquityIncentivePlanMember\nsrt:ChiefOperatingOfficerMember\n\n2023-05-01\n2023-05-01\n\n0001938046\n\nMGRX:TwoThousandTwentyTwoEquityIncentivePlanMember\nsrt:ChiefExecutiveOfficerMember\n\n2023-12-28\n2023-12-28\n\n0001938046\n\nMGRX:JohnathanArangoMember\n\n2024-03-28\n2024-03-28\n\n0001938046\n\nMGRX:JohnathanArangoMember\n\n2024-06-28\n2024-06-28\n\n0001938046\n\nMGRX:TwoThousandTwentyTwoEquityIncentivePlanMember\nMGRX:RaffiSahulMember\n\n2024-07-12\n2024-07-12\n\n0001938046\n\nMGRX:TwoThousandTwentyTwoEquityIncentivePlanMember\n\n2025-09-09\n2025-09-09\n\n0001938046\n\nMGRX:TwoThousandTwentyTwoEquityIncentivePlanMember\nsrt:ChiefExecutiveOfficerMember\n\n2025-09-09\n2025-09-09\n\n0001938046\n\n2026-03-16\n2026-03-16\n\n0001938046\n\nus-gaap:CommonStockMember\nMGRX:MrJacobCohenMember\n\n2022-08-31\n\n0001938046\n\nus-gaap:CommonStockMember\nMGRX:MrJacobCohenMember\n\n2022-08-31\n2022-08-31\n\n0001938046\n\nus-gaap:CommonStockMember\nMGRX:MrCohenMember\n\n2023-12-28\n\n0001938046\n\nus-gaap:CommonStockMember\nMGRX:MrCohenMember\n\n2023-12-28\n2023-12-28\n\n0001938046\n\nus-gaap:CommonStockMember\nMGRX:MrCohenMember\n\n2025-09-09\n\n0001938046\n\nus-gaap:CommonStockMember\nMGRX:MrCohenMember\n\n2025-09-09\n2025-09-09\n\n0001938046\n\n2025-01-01\n2025-12-31\n\n0001938046\n\nMGRX:RangeOneMember\n\n2026-03-31\n\n0001938046\n\nMGRX:RangeOneMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nMGRX:RangeTwoMember\n\n2026-03-31\n\n0001938046\n\nMGRX:RangeTwoMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nMGRX:RangeThreeMember\n\n2026-03-31\n\n0001938046\n\nMGRX:RangeThreeMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nMGRX:RangeFourMember\n\n2026-03-31\n\n0001938046\n\nMGRX:RangeFourMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nMGRX:RangeFiveMember\n\n2026-03-31\n\n0001938046\n\nMGRX:RangeFiveMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nsrt:MaximumMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nsrt:MinimumMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nMGRX:PrivatePlacementWarrantMember\n\n2022-08-31\n\n0001938046\n\nMGRX:PrivatePlacementWarrantMember\nMGRX:TwentyThreeAccreditedInvestorsMember\n\n2022-08-16\n2022-12-22\n\n0001938046\n\nMGRX:PrivatePlacementWarrantMember\n\n2026-03-31\n\n0001938046\n\nMGRX:PrivatePlacementWarrantMember\n\n2025-12-31\n\n0001938046\n\nus-gaap:WarrantMember\nus-gaap:IPOMember\n\n2023-03-20\n\n0001938046\n\nus-gaap:WarrantMember\nus-gaap:IPOMember\n\n2023-03-19\n2023-03-20\n\n0001938046\n\nus-gaap:CommonStockMember\nus-gaap:IPOMember\n\n2023-12-19\n\n0001938046\n\nus-gaap:CommonStockMember\nus-gaap:IPOMember\n\n2023-12-19\n2023-12-19\n\n0001938046\n\nMGRX:UnderwritingAgreementMember\nus-gaap:WarrantMember\n\n2024-01-22\n\n0001938046\n\nMGRX:UnderwritingAgreementMember\n\n2024-01-22\n2024-01-22\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:WarrantMember\n\n2024-04-04\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:WarrantMember\n\n2024-04-04\n2024-04-04\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:WarrantMember\n\n2024-06-28\n2024-06-28\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nus-gaap:WarrantMember\n\n2024-06-28\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nMGRX:WarrantOneMember\n\n2024-06-28\n2024-06-28\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nMGRX:WarrantOneMember\n\n2024-06-28\n\n0001938046\n\nMGRX:ConsultingAgreementMember\nMGRX:LevoHealthcareConsultingIncMember\n\n2024-08-22\n\n0001938046\n\nMGRX:ConsultingAgreementMember\nMGRX:LevoHealthcareConsultingIncMember\nus-gaap:RestrictedStockMember\n\n2024-08-22\n2024-08-22\n\n0001938046\n\nMGRX:ConsultingAgreementMember\nMGRX:LevoHealthcareConsultingIncMember\nus-gaap:RestrictedStockMember\n\n2024-08-22\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nMGRX:CommonStockPurchaseWarrantMember\n\n2024-12-18\n2024-12-31\n\n0001938046\n\nMGRX:SecuritiesPurchaseAgreementMember\nMGRX:CommonStockPurchaseWarrantMember\n\n2024-12-31\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-01-03\n2025-01-03\n\n0001938046\n\nus-gaap:CommonStockMember\n\n2025-01-03\n\n0001938046\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-01-06\n2025-01-06\n\n0001938046\n\nus-gaap:CommonStockMember\n\n2025-01-06\n\n0001938046\n\nus-gaap:CommonStockMember\nMGRX:SecuritiesPurchaseAgreementMember\n\n2025-01-06\n\n0001938046\n\n2025-01-06\n2025-01-06\n\n0001938046\n\nus-gaap:CommonStockMember\n\n2025-02-10\n\n0001938046\n\nus-gaap:CommonStockMember\n\n2025-02-11\n2025-02-11\n\n0001938046\n\nMGRX:CommonStockOneMember\n\n2025-02-11\n\n0001938046\n\nMGRX:CommonStockOneMember\n\n2025-02-11\n2025-02-11\n\n0001938046\n\nMGRX:CommonStockThreeMember\n\n2025-02-14\n\n0001938046\n\nMGRX:CommonStockThreeMember\n\n2025-02-14\n2025-02-14\n\n0001938046\n\nus-gaap:WarrantMember\n\n2025-06-02\n2025-06-02\n\n0001938046\n\nus-gaap:CommonStockMember\n\n2025-06-02\n2025-06-02\n\n0001938046\n\n2025-06-02\n\n0001938046\n\nus-gaap:WarrantMember\n\n2025-06-02\n\n0001938046\n\n2025-06-02\n2025-06-02\n\n0001938046\n\nus-gaap:WarrantMember\nMGRX:WarrantHolderMember\n\n2025-06-02\n2025-06-02\n\n0001938046\n\nMGRX:WarrantHolderMember\n\n2025-06-02\n\n0001938046\n\nsrt:MaximumMember\n\n2025-06-02\n2025-06-02\n\n0001938046\n\n2025-06-09\n\n0001938046\n\n2025-06-09\n2025-06-09\n\n0001938046\n\n2025-07-29\n\n0001938046\n\n2025-07-29\n2025-07-29\n\n0001938046\n\n2025-12-19\n2025-12-19\n\n0001938046\n\n2025-12-19\n\n0001938046\n\n2025-12-24\n2025-12-24\n\n0001938046\n\nus-gaap:WarrantMember\n\n2025-01-01\n2025-12-31\n\n0001938046\n\nus-gaap:WarrantMember\nsrt:MinimumMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:WarrantMember\nsrt:MaximumMember\n\n2026-03-31\n\n0001938046\n\nus-gaap:WarrantMember\nsrt:MinimumMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\nus-gaap:WarrantMember\nsrt:MaximumMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\n2025-06-23\n2025-06-23\n\n0001938046\n\nMGRX:BousteadAgreementMember\n\n2025-02-18\n\n0001938046\n\nMGRX:CompromiseSettlementAgreementAndMutualReleaseMember\n\n2025-05-05\n2025-05-05\n\n0001938046\n\nMGRX:IsaacConsultingAgreementMember\n\n2025-01-15\n2025-01-15\n\n0001938046\n\n2025-01-27\n\n0001938046\n\n2025-08-06\n2025-08-06\n\n0001938046\n\n2026-01-01\n\n0001938046\n\nMGRX:AmendedAndRestatedExecutiveEmploymentAgreementMember\nMGRX:MangoAndPeachesMember\n\n2025-04-24\n2025-04-24\n\n0001938046\n\nMGRX:AmendedAndRestatedExecutiveEmploymentAgreementMember\nMGRX:MrCohenMember\nsrt:MaximumMember\n\n2025-04-24\n2025-04-24\n\n0001938046\n\nMGRX:AmendedAndRestatedExecutiveEmploymentAgreementMember\nMGRX:MangoAndPeachesMember\nsrt:MinimumMember\n\n2025-04-24\n2025-04-24\n\n0001938046\n\nMGRX:AmendedAndRestatedExecutiveEmploymentAgreementMember\nMGRX:MrCohenMember\nsrt:MinimumMember\n\n2025-04-24\n2025-04-24\n\n0001938046\n\nMGRX:AmendedAndRestatedExecutiveEmploymentAgreementMember\nMGRX:MrCohenMember\n\n2026-03-31\n\n0001938046\n\nsrt:ChiefFinancialOfficerMember\n\n2026-03-20\n2026-03-20\n\n0001938046\n\nsrt:MaximumMember\nsrt:ChiefFinancialOfficerMember\n\n2026-03-20\n2026-03-20\n\n0001938046\n\n2025-05-14\n2025-05-14\n\n0001938046\n\nMGRX:PremisesMember\nMGRX:SVHQLLCMember\n\n2025-11-01\n\n0001938046\n\nMGRX:SharedSpaceMember\nMGRX:SVHQLLCMember\n\n2025-11-01\n\n0001938046\n\nMGRX:SVHQLLCMember\n\n2025-11-01\n2025-11-01\n\n0001938046\n\nMGRX:SVHQLLCMember\n\n2025-11-01\n\n0001938046\n\nMGRX:PremisesMember\nMGRX:SVHQLLCMember\n\n2025-11-01\n2025-11-01\n\n0001938046\n\nMGRX:SharedSpaceMember\nMGRX:SVHQLLCMember\n\n2025-11-01\n2025-11-01\n\n0001938046\n\nMGRX:SVHQLLCMember\n\n2022-09-28\n\n0001938046\n\nMGRX:SVHQLLCMember\n\n2026-03-31\n\n0001938046\n\nMGRX:SVHQLLCMember\n\n2026-01-01\n2026-03-31\n\n0001938046\n\n2025-09-30\n\n0001938046\n\nMGRX:ConsultingAgreementMember\nus-gaap:SubsequentEventMember\n\n2026-04-27\n2026-04-27\n\n0001938046\n\nMGRX:ConsultingAgreementMember\nus-gaap:SubsequentEventMember\n\n2026-04-27\n\n0001938046\n\nMGRX:ClarificationAgreementMember\nus-gaap:SubsequentEventMember\n\n2026-05-18\n2026-05-18\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\nutr:sqft\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n(Mark\nOne)\n\n \n\n☒\nQUARTERLY\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor\nthe quarterly period ended March 31, 2026\n\n \n\nOR\n\n \n\n☐\nTRANSITION\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor\nthe transition period from to\n\n \n\n**Commission\nFile Number: 001-41615**\n\n \n\n****\n\n \n\n**Mangoceuticals,\nInc.**\n\n(Exact\nname of Registrant as specified in its charter)\n\n \n\n**Texas**\n \n**87-3841292**\n\n(State\nor other jurisdiction of\n\nincorporation\nor organization)\n\n \n\n(I.R.S.\nEmployer\n\nIdentification\nNo.)\n\n \n \n \n\n**17130\nN. Dallas Parkway, Suite 240\nDallas, Texas**\n \n**75248**\n\n(Address\nof principal executive offices)\n \n(Zip\nCode)\n\n \n\n**(214)\n242-9619**\n\n**(Registrant’s\nTelephone Number, Including Area Code)**\n\n \n\n**Securities\nregistered pursuant to Section 12(b) of the Act:**\n\n \n\n**Title\nof each class**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which registered**\n\nCommon\nStock, par value $0.0001 per share\n \nMGRX\n \n\nThe\nNasdaq Stock Market LLC\n\n(The\nNasdaq Capital Market)\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 (the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was\nrequired to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge\naccelerated filer ☐\nAccelerated\nfiler ☐\n\nNon-accelerated\nfiler ☒\nSmaller\nreporting company ☒\n\n \nEmerging\ngrowth company ☒\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nNumber\nof shares of registrant’s common stock outstanding as of May 19, 2026: 17,167,422\n\n \n\n \n\n \n\n \n\n \n\n \n\n**TABLE\nOF CONTENTS**\n\n \n\n****\n\n**Cautionary Statement Regarding Forward-Looking Statements**\n3\n\n**Additional Information**\n5\n\n**Part I – FINANCIAL INFORMATION**\n6\n\n[Item\n1. Condensed Consolidated Financial Statements (unaudited)](#JA_004)\n6\n\n[*Condensed Consolidated Balance Sheets*](#aFF_001)\n6\n\n[*Condensed Consolidated Statements of Operations*](#aFF_002)\n7\n\n[*Condensed Consolidated Statements of Comprehensive Loss*](#aFF_003)\n8\n\n[*Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)*](#aFF_004)\n9\n\n[*Condensed Consolidated Statements of Cash Flows*](#aFF_005)\n10\n\n*Notes\nto Condensed Consolidated Financial Statements*\n11\n\n[Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#JA_005)\n40\n\n[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#m_001)\n61\n\n[Item 4. Controls and Procedures](#m_002)\n61\n\n \n \n\n**PART II - OTHER INFORMATION**\n62\n\n[Item 1. Legal Proceedings](#m_004)\n62\n\n[Item 1A. Risk Factors](#m_005)\n62\n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.](#m_006)\n65\n\n[Item 3. Defaults Upon Senior Securities.](#m_007)\n65\n\n[Item 4. Mine Safety Disclosures](#m_008)\n65\n\n[Item 5. Other Information.](#m_009)\n65\n\n[Item 6. Exhibits](#m_010)\n65\n\n** **\n\n****\n\n2\n\n \n\n** **\n\n****\n\n****\n\nCautionary\nStatement Regarding Forward-Looking Statements\n\n \n\nThis\nQuarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of the federal\nsecurities laws, including the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of Mangoceuticals,\nInc. (the “Company”) that are based on current expectations, estimates, forecasts, and projections about the industry\nin which the Company operates and the beliefs and assumptions of the management of the Company. In some cases, you can identify forward-looking\nstatements by the following words: “anticipate,” “believe,” “continue,” “could,”\n“estimate,” “expect,” “intend,” “may,” “ongoing,”\n“plan,” “potential,” “predict,” “project,” “should,”\nor the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking\nstatements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or\nby, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the\nstatements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity,\nperformance or achievements to be materially different from the information expressed or implied by the forward-looking statements in\nthis Report. Factors that might cause or contribute to such differences include, but are not limited to, those discussed elsewhere in\nthis Report, including under, or incorporated by reference into, “Risk Factors”, which factors include:\n\n \n\n●\nour ability to obtain additional funding, the terms of such funding, and dilution caused thereby;\n\n \n\n●\nthe effect of pandemics on our operations, sales, and the market for our products;\n\n \n\n●\nour ability to build and maintain our brand;\n\n \n\n●\ncybersecurity, information systems and fraud risks and problems with our websites;\n\n \n\n●\nour ability to expand and grow our operations, and successfully market our products;\n\n \n\n●\nchanges in, and our compliance with, rules and regulations affecting our operations, sales, and/or our products;\n\n \n\n●\nshipping, production or manufacturing delays;\n\n \n\n●\nour ability to increase sales;\n\n \n\n●\nregulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping;\n\n \n\n●\ncompetition from existing competitors or new competitors or products that may emerge;\n\n \n\n●\nour dependency on third-parties to prescribe and compound our products;\n\n \n\n●\nour ability to establish or maintain relations and/or relationships with third-parties;\n\n \n\n●\npotential safety risks associated with our products, including the use of ingredients, combination of such ingredients and the\ndosages thereof;\n\n \n\n●\nthe effects of changing inflation and interest rates, tariffs and trade wars, governmental shutdowns, economic downturns, including\npotential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the\nongoing Ukraine/Russian conflict and ongoing conflict in and around Israel) and other large-scale crises;\n\n \n\n3\n\n \n\n \n\n●\nour ability to protect intellectual property rights, claims that we have infringed on intellectual property rights, litigation and\nthe outcome thereof, claims that we have infringed on intellectual property rights, litigation and the outcome thereof;\n\n \n\n●\nour ability to attract and retain key personnel to manage our business effectively;\n\n \n\n●\nour ability to adequately support future growth; and\n\n \n\n●\nother risk factors included under “1A. Risk Factors” below.\n\n \n\nThese\nstatements are not guarantees of future performance or results. Forward-looking statements are based on information available at the\ntime the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels\nof activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking\nstatements in this Report. These factors include those set forth under, and incorporated by reference into, “Item 1A. Risk Factors”,\nbelow.\n\n \n\nIn\naddition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject.\nThese statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q. While we believe that\nsuch information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should\nnot be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are\ninherently uncertain, and investors are cautioned not to unduly rely on these statements.\n\n \n\nYou\nshould read the matters described in “Item 1A. Risk Factors” and the other cautionary statements made in this Report,\nand incorporated by reference herein and therein, as being applicable to all related forward-looking statements wherever they appear\nin this Report. We cannot assure you that the forward-looking statements in this Report will prove to be accurate and therefore prospective\ninvestors are encouraged not to place undue reliance on forward-looking statements. All forward-looking statements included herein speak\nonly of the date of the filing of this Report. All subsequent written and oral forward-looking statements attributable to the Company,\nor persons acting on its behalf, are expressly qualified in their entirety by the cautionary statements above. Other than as required\nby law, we undertake no obligation to update or revise these forward-looking statements, even though our situation may change in the\nfuture.\n\n \n\n**Summary\nRisk Factors**\n\n \n\nOur\nbusiness is subject to varying degrees of risk and uncertainty. Investors should consider the risks and uncertainties summarized below,\nas well as the risks and uncertainties discussed in, and incorporated by reference in, Part II, Item 1A, “Risk Factors”\nof this Quarterly Report on Form 10-Q and Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the\nyear ended December 31, 2025, which was filed with the Securities and Exchange Commission on April 1, 2026 (the “2025 Annual\nReport”). Investors should also refer to the other information contained or incorporated by reference in this Quarterly Report\non Form 10-Q, including our financial statements and related notes, and our other filings made from time to time with the Securities\nand Exchange Commission. Our business operations could also be affected by factors that we currently consider to be immaterial or that\nare unknown to us at the present time. If any of these risks occur, our business, financial condition, and results of operations could\nbe materially and adversely affected, and the trading price of our common stock could decline or our common stock could become worthless:\n\n \n\nOur\nbusiness is subject to numerous risks and uncertainties, including those described below and elsewhere in this Report. These risks include,\nbut are not limited to, the following:\n\n \n\n●\nOur need for additional funding, the availability and terms of such funding, and dilution caused thereby;\n\n \n\n4\n\n \n\n \n\n●\nWe have a limited operating history, have produced only a limited amount of products and have generated only limited revenues to\ndate;\n\n \n\n●\nOur ability to execute our growth strategy and scale our operations and risks associated with such growth, and our ability to\nattract members and customers;\n\n \n\n●\nThe effect of pandemics and governmental responses thereto on our operations, those of our vendors, our customers and the economy in\ngeneral;\n\n \n\n●\nRisks associated with our products which have not been, and will not be expected to be, approved by the U.S. Food and Drug\nAdministration (“FDA”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to\nprevent the possibility of serious patient injury and death;\n\n \n\n●\nRisks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal\nFood, Drug and Cosmetic Act (“FFD&C Act”) provided by Section 503A thereof;\n\n \n\n●\nOur significant reliance on related party transactions and risks associated with such related party relationships and\nagreements;\n\n \n\n●\nThe effect of data security breaches, malicious code and/or hackers;\n\n \n\n●\nCompetition and our ability to create a well-known brand name;\n\n \n\n●\nChanges in consumer tastes and preferences;\n\n \n\n●\nMaterial changes and/or terminations of our relationships with key parties;\n\n \n\n●\nSignificant product returns from customers, product liability, recalls and litigation associated with tainted products or products\nfound to cause health issues;\n\n \n\n●\nOur ability to innovate, expand our offerings and compete against competitors which may have greater resources;\n\n \n\n●\nOur ability to prevent credit card and payment fraud;\n\n \n\n●\nRisks associated with inflation, changes in interest rates, tariffs and trade wars, and economic downturns, including potential\nrecessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing\nUkraine/Russian conflict, the Israel/Hamas conflict and the Iran/U.S. conflict) and other large-scale crises;\n\n \n\n●\nThe risk of unauthorized access to confidential information;\n\n \n\n●\nOur ability to protect our intellectual property and trade secrets, claims from third-parties that we have violated their\nintellectual property or trade secrets and potential lawsuits in connection therewith;\n\n \n\n●\nOur and our providers’ ability to comply with government regulations, changing regulations and laws, penalties associated with\nany non-compliance (inadvertent or otherwise), the effect of new laws or regulations, and our ability to comply with such new laws\nor regulations;\n\n \n\n●\nOur reliance on our current management and the terms of their employment agreements with us;\n\n \n\n●\nThe outcome of lawsuits, litigation, regulatory matters or claims;\n\n \n\n●\nCertain terms and provisions of our governing documents which may prevent a change of control, and which provide for indemnification\nof officers and directors, limit the liability of officers or directors, and provide for the board of director’s ability to\nissue blank check preferred stock; and\n\n \n\n●\nThe volatile nature of the trading price of our common stock; dilution experienced by investors in the offering; and dilution which\nmay be caused by future sales of securities.\n\n \n\nAdditional\nInformation\n\n \n\nUnless\nthe context otherwise requires, all references in this Quarterly Report on Form 10-Q to “we,” “us,”\n“our,” “our company,” and “MangoRx” refer to Mangoceuticals, Inc. The MangoRx\ndesign logo, “MangoRx,” and our other registered or common law trademarks, service marks, or trade names appearing\nin this Quarterly Report on Form 10-Q are the property of Mangoceuticals, Inc. Other trade names, trademarks, and service marks used\nin this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, we have omitted the ®\nand ™ designations, as applicable, for the trademarks we name in this Quarterly Report on Form 10-Q.\n\n** **\n\n5\n\n \n\n** **\n\nPart\nI – FINANCIAL INFORMATION"}